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Defective expression of frataxin is responsible for the degenerative disease Friedreich’s ataxia. Frataxin is a protein required for
cellsurvivalsince completeknockoutislethal.Frataxinprotects tumorcellsagainstoxidativestressandapoptosisbutalsoacts
as a tumor suppressor. The molecular bases of this apparent paradox are missing. We therefore sought to investigate the
pathways through which frataxin enhances stress resistance in tumor cells. We found that frataxin expression is upregulated in
several tumor cell lines in response to hypoxic stress, a condition often associated with tumor progression. Moreover, frataxin
upregulation in response to hypoxia is dependent on hypoxia-inducible factors expression and modulates the activation of the
tumor-suppressor p53. Importantly, we show for the ﬁrst time that frataxin is in fact increased in human tumors in vivo. These
results show that frataxin participates to the hypoxia-induced stress response in tumors, thus implying that modulation of its
expression could have a critical role in tumor cell survival and/or progression.
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Friedreich’s ataxia (FRDA) is a degenerative inherited
disease because of deﬁcient expression of the nuclear-
encoded mitochondrial protein frataxin.
1 Frataxin is required
for organismal development, since its complete loss results in
embryonic lethality in mouse,
2 in plant Arabidopsis
3 and
in developmental arrest in the nematode C. elegans.
4 Partial
expression of frataxin allows instead organismal development
and survival, yet results in progressive degeneration of
speciﬁc tissues. In fact, frataxin deﬁciency in humans critically
affects survival of large primary neurons of the dorsal root
ganglia, cardiomyocytes and pancreatic b-cells, accounting
for FRDA syndromic features.
1
Frataxin is therefore crucial for cell survival. Although
the exact function of this protein is still unclear, it has
been implicated in different biological functions, such as
iron homeostasis,
5 iron–sulfur cluster (ISC) biosynthesis,
6
protection from oxidative stress and apoptosis.
7 Conﬂicting
results have been reported on the role of frataxin in cellular
growth: both frataxin knockdown and frataxin overexpression
were shown to impair cell growth.
8–11 Very little is known
regarding the molecular regulation of frataxin expression:
histone deacetylase inhibitors, erythropoietin, cisplatin,
3-nitropropionic acid and hemin increase levels of frataxin
in vitro (for review, see ref. 12). Moreover, transcription
factors peroxisome proliferator-activated receptor gamma,
13
and hypoxia-inducible factor-2 alpha (HIF-2a),
14 positively
regulate frataxin expression. However, the molecular
bases underlining the potential role of frataxin in cancer are
unknown.
Hypoxia is a characteristic feature of most solid tumors that
promotes the angiogenic switch necessary for tumor progres-
sion.
15 The hypoxic environment found in tumors is not only
dramatically associated with tumor progression but also
confers tumor resistance to chemotherapy and radiotherapy.
Cells under hypoxic stress can either develop an adaptive
response, increasing the rate of glycolysis and angiogenesis,
or undergo cell death through apoptosis and/or necrosis.
16,17
The ability of tumor cells to maintain a balance between
adaptation to hypoxia and cell death is mainly mediated by
HIFs, which are essential for the regulation of the expression
of a large number of hypoxia-responsive genes.
16,17 HIFs
are heterodimers consisting of either HIF-1a or HIF-2a bound
to HIFb/ARNt subunit. Although HIF-1b is constitutively
expressed, both HIFa subunits are modulated by oxygen
availability. Under normoxia, HIFa subunits are degraded by
the proteasome through binding to the Von Hippel–Lindau E3
ligase. Low oxygen tension stabilizes the HIFa subunits by
inhibiting its degradation thus activating hypoxic adaptation
responses. HIFs regulate the expression of genes containing
conserved hypoxia-responsive element (HRE).
18 Murine
frataxin was shown to possess an HRE and its expression is
indeed controlled by HIF-2a.
14 In addition, a direct correlation
between upregulation of HIF expression and tumor progres-
sion is well documented.
16
Stabilization of the tumor-suppressor p53 is one of the
many cellular responses triggered by hypoxic conditions.
19,20
p53 itself is indeed modulated by HIF transcription factors
21
and is involved in the metabolic alterations, which occur in
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22 Hypoxia associated with tumor progression,
not only results in enhanced stabilization of the master
regulator HIF-1a but also in an increased leakage of reactive
oxygen species (ROS) from the mitochondrial electron
transport chain.
23 Mitochondrial ROS production in turn
activates p53 (ref. 24) while frataxin dampens oxidative
stress.
25 Moreover, a link between frataxin, oxidative stress
and p53 has already been observed in C. elegans where the
absenceofcep-1,theC.elegansp53homologue,signiﬁcantly
suppresses the increase in lifespan induced by reduced
expression of the frataxin homologue frh-1 (ref. 26). cep-1
also regulates the induction of gst-4 (ref. 27), an antioxidant
gene controlled by the redox-transcription factor skn-1, the
C. elegans homolog of Nfr2, whose activation is impaired
in human cells with defective frataxin expression.
28
Considering that hypoxia is a major stress signal for tumor
cells, and that the murine frataxin is regulated by HIF, we
hypothesized that frataxin could participate in tumor adapta-
tion to hypoxia by regulating p53-dependent metabolic path-
ways. In this study, we found that hypoxia induces frataxin
expression in different human tumor cell lines in a HIF-1a-
dependent manner. In addition, frataxin silencing in tumor
cellspreventedhypoxia-inducedp53activation.Ourdatathus
suggest that frataxin expression could have a critical role in
tumor cell survival and/or progression. Importantly, in support
of this idea, we now provide evidence for an in vivo increasein
frataxin in human glioblastoma and colon cancer samples.
Results
Hypoxia induces frataxin expression in tumor cells. As
tumor progression is associated with hypoxia, we analyzed
frataxin expression on hypoxic stress in several tumor cell
lines, such as two human glioblastoma cell lines U87 and
U118, colon carcinoma HCT116 and human epithelial
cervical carcinoma HeLa cells. The effect of hypoxia was
also tested on immortalized B lymphoblasts derived from
a FRDA patient and on control-matched immortalized
B lymphoblasts derived from a healthy brother. Cells were
subjected to hypoxia (o1% O2) and collected at the time
indicated. Longer exposures to hypoxia resulted in cell death
(data not shown). As expected, HIF-1a protein expression
increased on hypoxia compared with untreated cells
(21% O2) (Figure 1). Importantly, both frataxin protein
(Figure 1) and mRNA (Supplementary Figure 1) were
signiﬁcantly upregulated following severe hypoxic stress in
all the cell types analyzed. Frataxin expression was induced in
the different cell lines at different time points and with different
intensity, probably reﬂecting differential cell-type sensitivity to
low oxygen. Of note, transcriptional upregulation of frataxin
appears to be modest compared with the effect on protein
level. This observation suggests that, consistent with our
recent report describing frataxin stability under proteasome
control in normoxia,
29 additional mechanisms for frataxin
protein stabilization could also exist in hypoxic conditions.
Hypoxia-induced frataxin upregulation is mediated by
HIF. HIFs are main mediators of hypoxia. Under low oxygen
conditions, they translocate to the nucleus where they act as
transcription factors for different HRE-containing genes. As
murine frataxin was shown to possess an HRE for HIF-2a,
we assessed whether frataxin upregulation in response to
hypoxia in human cancer cells is mediated through the HIF
pathway. We took advantage of glioblastoma cell lines TB10,
U87 and U118, which stably express shRNA against HIF-1a,
resulting in 70–80% knockdown of its expression.
30 Wild-
type cells and cells stably expressing shHIF-1a were
subjected to hypoxia and frataxin expression was analyzed.
As expected, on shRNA treatment, hypoxia-induced HIF-1a
expression was signiﬁcantly prevented in cells stably
expressing shHIF-1a. Importantly, while HIF-2a expression
was unchanged, the induction of frataxin on hypoxic stress
was almost completely abolished (Figure 2). These results
suggest that frataxin induction in response to hypoxia is
controlled by HIF-1a in human cells.
Frataxin deﬁciency differently affects p53 activation in
normoxia or hypoxia. Hypoxia modulates the activation
of the tumor-suppressor p53, one of the most important
defender against tumor development.
22 We analyzed
hypoxia-induced p53 activation in immortalized B lympho-
blasts derived from a FRDA patient, compared with control-
matched immortalized B lymphoblasts derived from a healthy
brother. Cells undergoing hypoxia showed p53 phosphory-
lation at ser15, a classical marker of p53 activation.
Interestingly, frataxin-defective cells had increased basal
Figure 1 Hypoxic stress upregulates frataxin. (a) FRDA patient-derived B cells
(FRDA) and respective control cells (Healthy), human glioblastoma U87, U118,
colon carcinoma HCT116 and HeLa cells were placed for different time exposure
(24hforFRDA,healthycontrol-derivedBcellsandHCT116,18hforU87,U118and
6h for HeLa) into hypoxic chamber and frataxin (Fxn), tubulin (Tub) and HIF-1a
expression was analyzed by western blot. Data are representative of 6, 11, 4, 7, 5
and 3 independent experiments for FRDA, Healthy, U87, U118, HeLa and HCT116
respectively. (b) Densitometric quantiﬁcation of frataxin upregulation. Frataxin
expression was normalized with tubulin and frataxin expression in normoxia set
to one. Data represent the mean±1 S.E.M. from the different independent
experiments performed for each cell line described in a. P-values were calculated
with Student’s t-test and were statistically signiﬁcant (Po0.05) for all cell lines
analyzed
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Cell Death and Diseaselevel of phosphorylated p53 but a less efﬁcient activation of
p53 on hypoxia (Figure 3a).
To further address the role of frataxin in modulating p53, we
also interfered with frataxin expression using a shRNA-based
approach in HeLa and U118 cell line, achieving a 60–70%
frataxin knockdown. Cells were then placed into hypoxic
conditions and p53 activation was analyzed by western blot.
Similarly to FRDA cells, frataxin knockdown HeLa (Figure 3b)
and U118 (Figure 3c) cells had increased basal level
of phosphorylated p53 compared with control cells. On
hypoxia exposure, however, both HeLa (Figure 3b) and
U118 (Figure 3c) failed to upregulate frataxin and to activate
p53. Thus, cells with slightly activated p53 might respond less
efﬁciently to hypoxia. Importantly, normal frataxin levels
appear to be required for optimal p53 activation following
hypoxia.
Frataxin is upregulated in human tumor samples
in vivo. To assess whether frataxin levels are modulated
in hypoxic tissues in vivo, frataxin was quantitated in human
glioblastoma and colon carcinoma tumor samples. Analysis
was performed comparing central tumor sample with the
Figure 2 HIFs mediate hypoxia-induced frataxin upregulation. Left panels:
human glioblastoma cells TB10 (a), U87 (b) and U118 (c) wild type or stably
interfered for HIF-1a (shHIF-1a) were exposed to severe hypoxia for 18h and
frataxin (Fxn), tubulin (Tub), HIF-1a and HIF-2a expression analyzed. Data are
representative of four, three and three independent experiments for TB10, U87 and
U118 cells, respectively. Right panels: densitometric quantiﬁcation of frataxin
upregulation. Frataxin expression was normalized with tubulin and frataxin
expression in normoxia set to one. Data represent the mean±1 S.E.M. from the
different independent experiments performed for cell lines described in left panels.
P-values were calculated with Student’s t-test: *Po0.05; **Po0.01
Figure 3 Frataxin deﬁciency prevents p53 activation in response to hypoxia.
(a)FRDApatient-derivedBcells(FRDA)andrespectivecontrolcells(Healthy)were
placed into hypoxic chamber for 18h and frataxin (Fxn), actin (Act), total p53
(p53Tot) and phosphorylation at serine 15 of p53 (pS15-p53) expression analyzed.
Data are representative of six independent experiments. (b) HeLa cells were
transiently transfected with plasmid for frataxin gene interference (shFxn) each
2 days. Frataxin (Fxn), actin (Act), total p53 (p53Tot) and phosphorylation at serine
15ofp53(pS15-p53)wereanalyzedafterthreeroundsoftransfectionandexposure
or not to hypoxic conditions for 18h. Data are representative of three independent
experiments (c) hFxnRNAi and control U118 cells were treated for 5 days with
doxycycline. Frataxin (Fxn), actin (Act), total p53 (p53) and phosphorylation at
serine 15 of p53 (pS15-p53) expression were analyzed after exposure or not to
hypoxia for 18h. Data are representative of four independent experiments
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Cell Death and Diseaseadjacent healthy tissue of the same patient. Strikingly,
frataxin resulted to be signiﬁcantly upregulated in 485%
of tumor samples analyzed (Figures 4a and b). Frataxin
expression was upregulated in 12 out of 14 glioblastoma
(Figure 4a), and in 17 out of 20 colorectal carcinoma tumor
samples (Figure 4b), compared with the adjacent healthy
tissue. The average frataxin upregulation resulted in
2.50- and 1.42-fold increase in glioblastoma and colorectal
carcinoma tumors, respectively, and was statistically signi-
ﬁcant both in glioblastomas and colorectal carcinomas
(Po0.01).
In one case of glioblastoma, we ﬁrst obtained surgical
resections from the primary tumor and then from a relapse. In
the relapse samples, the tumor core presented extended
necrotic areas, a feature usually associated to severely
hypoxic tissue and the adjacent peripheral tissue was
inﬁltratedbyneoplasticcells.Interestingly,frataxinexpression
was higher in the relapse sample, compared with the primary
sample, both in the core and in the adjacent peripheral areas
(Figure 5a).
In addition, for other six glioblastoma patients, two
peripheral healthy samples adjacent to the tumor resection
edge were collected. P1 is closer than P to the tumor central
core. Interestingly, we could correlate frataxin expression
level with the distance to the tumor core sample: the closer is
the peripheral sample to the tumor core, the higher is the
frataxin expression (Figure 5b).
Moreover, although the lack of information regarding p53
mutations in the samples analyzed does not allow to directly
link frataxin expression to p53 activation, according to what
we observed in human cell lines undergoing hypoxia, frataxin
upregulation correlated with p53 expression and activation
(Supplementary Figure 2).
Discussion
This study shows that frataxin is upregulated on hypoxia in
tumor cell lines and that this event is dependent on HIF-1a.
Moreover, frataxin is required for optimal p53 activation
following hypoxia in tumor cell lines. Importantly, here we
report that frataxin is in fact upregulated in vivo in human
glioblastoma and colon tumor samples.
Tumor proliferation depends on adequate nutrients and
oxygen supply but tumor cells also need to survive under
hostile conditions that include hypoxia and increased oxida-
tive stress. The ability of tumor cells to maintain a balance
Figure 4 Frataxin is upregulated in human glioblastoma and colon cancer. Protein extracts (100mg) were prepared from human glioblastoma and colorectal carcinoma
(Tumor) and corresponding normal samples (Healthy). Frataxin expression was analyzed by western blot and normalized with tubulin and b-actin for glioblastoma (a) and
coloncarcinoma(b),respectively,and frataxinexpressionin healthysamples set to one.Thedensitometricquantiﬁcation of normalizedfrataxinin thevarioussamplesas well
as mean upregulation is indicated (mean±1 S.E.M.). Statistical analysis was performed by Student’s t-test: *Po0.05; **Po0.01
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Cell Death and Diseasebetween adaptation to hypoxia and cell death is mainly
mediated by transcription factors HIFs. Moreover, mito-
chondrial alterations including frataxin downregulation are
observed in HIF-2a knockout mice,
31 and murine frataxin
promoter is under control of HIF-2a.
14 We report that frataxin
levels are increased in vivo both in human colon carcinoma
and human glioblastoma tumors. Consistent with the HIF
upregulation observed in tumors, especially in human glioma
tissues,
16,32 we found that hypoxia induces frataxin accumu-
lation in a HIF-1a-dependent manner in human glioblastoma
TB10, U87 and U118 cell lines.
Frataxin binds iron and is involved in iron metabolism.
33
ConsideringthatironcontrolsHIFsdegradationandthatHIFs,
in turn, can regulate iron metabolism modulating the levels of
hepcidin, a functional interplay between HIFs and frataxin
is expected. Although frataxin deﬁciency was reported to
result in upregulation of HIF-1a proteins in cardiomyocytes
of conditional frataxin knockout mutant mice with evident
cardiomyopathy,
34 we could not detect any signiﬁcant
differences of HIFs protein expression between healthy
control and FRDA lymphoblasts or between wild-type and
shFxn HeLa and U118 cells, both in normoxia and hypoxia
conditions. Moreover, a role for HIF-2a but not HIF-1a in iron
absorption of intestinal epithelium in mice has been reported:
only HIF-2acan regulate the irontransporterDMT1 (ref.35). It
is noteworthy that contrasting effects between HIF-1a and
HIF-2a have also been described on p53 activation in human
cells. Although HIF-1a activates p53 (ref. 19), HIF-2a has
been recently reported to inhibit p53 and ROS production.
21
Considering that murine frataxin is controlled by HIF-2a but
that in our cell system human frataxin upregulation
in response to hypoxia depends primarily on HIF-1a, it would
be interesting to further investigate whether such a discre-
pancy depends on cell and/or tissue type or on species
differences.
Given the role of frataxin in ISC biogenesis, the HIF-1a-
mediated frataxin upregulation is apparently in contrast with
the pathways leading to mitochondrial dysfunctions in hypoxic
cells.
17 In this context, miR-210, which is a key microRNA
upregulated by HIF-1a under hypoxic conditions, leads to
downregulation of the scaffold protein ISCU in order to
repress the mitochondrial electron transport and the Krebs’
cycle.
36 However, the repression of ISCU by miR-210
concomitantly contributes to the generation of ROS during
hypoxia,
36,37 and frataxin, in addition to its function as iron
chaperone,alsohasakeyfunctionintheadaptiveresponseto
oxidative stress.
25 As oxidative stress correlates with aggres-
siveness of tumors and promotes tumor cell survival under
hypoxic conditions,
15 frataxin induction may contribute to
tumor cells survival under hypoxia by regulating cells anti-
oxidant response. A ﬁne-tuned regulation already exists
between hypoxia, HIF, p53 activation and ROS production:
hypoxia stimulates mitochondrial ROS production, which
modulates HIF-1a
38 and HIF-1a, in turn, has a crucial
homeostaticroleinmanagingoxygenconsumptiontobalance
ATPandROSproduction.
17Moreover,hypoxiaactivatesp53,
which has both pro-oxidant and anti-oxidant effects.
22 We
now add a new player to this complex loop by providing data
showing that frataxin deﬁciency induces p53 activation in
normoxiawhile preventingitonhypoxia.Frataxindeﬁciencyin
FRDA patients leads to increased ROS production,
25 which
couldinturnactivatep53resemblinghypoxicstresscondition.
This basal stress could then interfere with further adequate
adaptive hypoxic responses preventing optimal p53 activa-
tion. In support of our ﬁndings, several evidences point
to differential p53 biological responses depending on the
degree of damage or stress as a conserved evolutionary
mechanism from nematodes to mammals.
22,26 Moreover,
consistent with a role of frataxin in regulating p53 responses,
we have previously shown that frataxin deﬁciency modulates
longevity and antioxidant gst-4 activation in C. elegans,
Figure 5 A correlation between frataxin expression and tumor progression
could be found in different human glioblastoma patients. Protein extracts (100mg)
were prepared from human glioblastoma and corresponding normal samples.
Frataxin(Fxn)expressionwasnormalizedwithtubulin(Tub)andfrataxinexpression
in healthy samples set to one. (a) Frataxin expression was analyzed in patient
healthy (H) and tumoral (T) samples after ﬁrst surgical resection and in neoplastic
inﬁltrated peripheral tissue (P) and tumoral (T2) samples after second surgical
resection because of tumor relapse. (b) Frataxin was analyzed in six different
peripheral (P and P1) samples. P1 is closer to central tumor core (T). Patient
numbers (1, 2, 3, 4, 13 and 14) are referred to Figure 4a. The densitometric
quantiﬁcation of normalized frataxin in the various samples as well as mean
upregulation is indicated (mean±1 S.E.M.). Statistical analysis was performed by
Student’s t-test: *Po0.05
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26,27anda recentreportdescribes
partners proteins of p53 and ATM signiﬁcantly altered in
FRDA patients.
39 Overall, frataxin levels may contribute to the
survival pathways of tumor cells via a ﬁne-tuned regulation of
the anti-oxidant response under hypoxic environment, likely
inﬂuencing metabolic pathways by modulating the hypoxia-
induced p53 stress response. The mechanisms underlying
differentialmodulation ofp53activationbyfrataxinexpression
levels in normoxia and hypoxia with possible consequent
recruitment of different p53 downstream targets will require
further investigation.
Last but not least, considering that in FRDA, frataxin
expression is inversely correlated with disease onset,
progression and severity, it is noteworthy that frataxin protein
level could be upregulated on hypoxia even in FRDA patient
derived lymphoblastoid cells. Although hypoxia cannot be
considered as a therapeutic strategy for this disease, further
unraveling the mechanisms contributing to hypoxia-induced
frataxin upregulation could be crucial to identify novel drugs
capable of increasing frataxin level in FRDA patients.
In summary, frataxin is crucial for cell life since reduction of
its expression leads to neurodegenerative disease FRDA and
completeknockoutislethalinseveralorganismssuchasmice
and plants. Frataxin overexpression can protect tumor cells
from apoptosis but can also act as a tumor suppressor. We
herein provide explanation for this apparent paradox showing
that frataxin participates, by regulating p53 acti-
vation, in tumor adaptation to hypoxia, a critical feature
associated with tumor growth and progression, thus suggest-
ing that frataxin levels can inﬂuence tumor cell fate. We show
indeed for the ﬁrst time that frataxin is increased in vivo
in human tumor tissues.
Materials and Methods
shRNA construct (shFxn). Frataxin was depleted in human cells by RNAi
using a pSUPER vector-based approach. Self-complementary inverted repeat
sequences of frataxin (19 nucleotide long frataxin gene-speciﬁc targeting sequence
50GTTCGAACCAACGTGGCCT-30, position 167–185 of the coding sequence),
spaced by 9 base loop region 50TTCAAGAGA-30 were synthesized (Invitrogen,
San Giuliano Milanese, Italy) as single-strand oligonucleotides. These 64 base long
oligonucleotides containing the coding and complementary sequence of these
components, together with BglII and HindIII restriction site sequences at the 50 and
30 ends respectively, were then annealed by heating to 891C 10min and cooled
down to 691C in 30min, and then to 651C 10min, in 50mM Tris-HCl, 10mM
MgCl2, 10mM DTT, 1mM ATP, 25mg/ml BSA, 10% DMSO. Successful annealing
was checked by agarose gel electrophoresis, and the obtained double-stranded
DNA was cloned into the pSUPER vector via the BglII and HindIII restriction sites.
All constructs were checked by DNA sequencing.
TheinduciblehFxnRNAiconstruct(pSUPERIOR.PUROvector)andpcDNA6/TR
plasmid were a kind gift of Dr. Cortopassi.
40
Cell culture, transfections and hypoxia. Immortalized GM15850B
lymphoblasts, from a clinically affected FRDA patient, and immortalized
GM15851B lymphoblasts from a clinically unaffected brother of GM15850 were
obtained from NIGMS Human Genetic Cell Repository, Coriell Institute for Medical
Research (Camden, NJ, USA) and were cultured in RPMI 1640 supplemented with
15% fetal bovine serum. HeLa, U87, U118, HCT116 and TB10 cells were cultured
in DMEM supplemented with 10% fetal bovine serum.
When described, these cells were transiently transfected with DNA constructs
using Lipofectamine 2000 (Invitrogen), following the manufacturer’s instructions. To
interfere with frataxin expression, HeLa cells were transfected with shRNA plasmid
forfrataxingene(shFxn).Threeroundsoftransfectionevery2dayswereperformed
to achieve a 60–70% frataxin knockdown.
To create severe hypoxic environmental conditions, cells were placed
into a modular incubator chamber (Billups-Rothenberg, Del Mar, CA, USA)
and gas without oxygen (95%N2,5 %C O 2) was ﬂushed into the chamber for
10min. Cells were then cultured into a normal CO2 incubator for different
time periods.
Generation of stably shHIF-1a cell lines. Glioblastoma cell lines TB10,
U87 and U118 with silencing of HIF-1a were obtained, as previously described, by
retroviral mediated expression of shRNA targeting nucleotide speciﬁc for HIF-1a
sequence resulting in 70–80% knockdown of its expression.
30
Generationofstabledoxycycline/tetracycline-induciblehFxnRNAi
cell line. Human U118 glioblastoma cells stably transfected using Lipofectamine
2000 (Invitrogen) with pcDNA6/TR plasmid, therefore expressing the tetracycline
repressor, were ﬁrst generated by 10 days selection with blasticidin hydrochloride
(Invitrogen) 2mg/ml. Cells were maintained in DMEM supplemented with 10%
tetracycline-free fetal bovine serum (HyClone, Rockford, IL, USA).
Stably expressing pcDNA6/TR U118 cells were then transfected with inducible
hFxnRNAi construct or the empty pSUPERIOR.PURO vector as a control for the
induciblesystem.At24haftertransfection,thecellsweresplitandgrowninmedium
containing 1.5mg/ml puromycin (Sigma, Milan, Italy). Single clones were isolated
and expanded.
The efﬁciency of the inducible RNAi system was established analyzing frataxin
mRNA levels by quantitative real-time PCR after 5 days of treatment with 8mg/ml
doxycycline (Sigma) of hFxnRNAi and control clones. Three hFxnRNAi clones
showing 470–80% frataxin reduction were selected, as well as control clones in
which frataxin level remained unchanged (data not shown).
Quantitative RT-PCR analysis. Total RNA (500ng) was retrotranscribed
using SuperScript VILO cDNA Synthesis Kit (Invitrogen) according to the
manufacturer’s instructions. One-twentieth of the cDNA was used to quantify the
transcripts by real-time RT-PCR employing the 7900HT Fast Real-Time PCR
System by Applied Biosystem (Carlsbad, CA, USA). Gene speciﬁc-primers were
designed by the Probe Finder software (Roche Applied Science, Milan, Italy) and
the cDNA was ampliﬁed and quantiﬁed using the SensiMix dT kit by Quantace
(Bioline,London,UK) accordingto themanufacturer’sinstructions. The tata-binding
protein mRNA was used as housekeeping invariant reference gene and the relative
quantitywascalculatedaccordingly.Speciﬁcforwardprimerforfrataxinissituatedin
the third exon: 50-CATACACGTTTGAGGACTATGATGTCT-30 and speciﬁc reverse
primer situated in the fourth exon: 50-TTTGGCGTCTGCTTGTTGATC-30.
Western blot. Total cell extracts were prepared in ice-cold modiﬁed RIPA lysis
buffer (10mM sodium phosphate pH 7.2, 150mM NaCl, 1% NP-40, 1% sodium
deoxycholate,0.1%SDS, 2mMEDTA)supplementedwithcompleteproteaseinhibitor
cocktail (Roche Diagnostics, Milan, Italy). Cell lysates (100mg) were resolved by SDS-
PAGE and analyzed by immunoblot with speciﬁc mAb anti-frataxin (Immunological
Sciences,Rome,Italy),mAbanti-tubulin(Sigma),mAbanti-HIF-1a(BectonDickinson,
Milan,Italy),mAbanti-HIF-2a(SantaCruzBiotechnology,Heidelberg,Germany),mAb
anti-bactin (Sigma), mAb anti p53 (Santa Cruz Biotechnology) mAb anti
phosphorylated p53 (ser 15) (Cell Signaling Technology, Danvers, MA, USA) using
ECL system detection (GE Healthcare Europe GmbH, Milan, Italy). Densitometric
analyses were performed using ImageJ software (W Rasband, National Institutes of
Health, Bethesda, MD, USA; http://rsb.info.nih.gov/ij).
Total cell extracts from human tumor samples. Colorectal
adenocarcinoma and corresponding normal tissue from the same patients were
obtained from 20 patients who underwent surgical resection. Glioblastoma tissue
and corresponding normal counterpart adjacent to the tumor (resection edge) from
the same patients were obtained from 14 patients who underwent surgical
resection. The normal corresponding tissues were conﬁrmed to be tumor-free by
histological analysis. Each sample was frozen in liquid nitrogen, stored at  801C,
and subsequently homogenized on ice, in ice-cold modiﬁed RIPA lysis buffer
supplemented with complete protease inhibitor cocktail. Frataxin, p53 and p53
phosphorylation were analyzedby western blot. Protein expression in human tumor
samples was tested in duplicates or triplicates when possible.
Statistical analysis. The signiﬁcance of differences between populations of
datawereassessedaccordingtotheStudent’st-testwithalevelofsigniﬁcanceofat
least Po0.05 (alpha conventionally equal to 0.05).
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